

AMICUS CHANGES NAME TO “SWIXX BIOPHARMA SA”

ANNOUNCEMENT NO. 24

May 29th, 2019

Baar, Switzerland – Amicus SA today announces that it has determined to change its name to “Swixx Biopharma SA.” Amicus’ holding company, Amicus SA, has been officially re-named Swixx Biopharma SA in Switzerland as of May 29th, and similar name migrations (to Swixx Biopharma) are underway for all Amicus’ legal entities in the EU (Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia, and Slovenia) and also for Amicus’ new Russian subsidiary. All these name changes should be completed by early July 2019.

Please note that Amicus SA’s / Swixx Biopharma SA’s subsidiaries in the non-EU West Balkan countries of Albania, Bosnia-Herzegovina, Kosovo, Macedonia, Montenegro and Serbia will not be affected by this name change and will continue to operate under their current locally-registered names containing “Amicus.” Those companies of course will continue to be 100%-owned subsidiaries of Swixx Biopharma SA of Baar, Switzerland.

The name change should not have any effect on Amicus/Swixx operations or legal obligations to clients and partners. Nor does it connote a change in the ownership structure of the company, which continues uninterrupted. If you have any concerns or questions, please do not hesitate to reach out to Amicus’ Corporate Counsel, Gabriela Zelenkova or other corporate functions (contact details appended below). Please note that Amicus is already in the process of reaching out to all officially-designated partner contact points regarding the name change and associated reporting, regulatory and safety filings. This process should be completed in the next few weeks.

Both Amicus’ website and company email addresses will move to the new corporate name and a new email address (ending @swixxbiopharma.com) during the course of June, although for the next year emails sent to the old email addresses ending amicuspharma.eu will be forwarded automatically to the new @swixxbiopharma.com address.

About Swixx Biopharma SA (previously Amicus SA)

Swixx Biopharma now operates fully-owned subsidiaries across Central and Eastern Europe, offering cohesive coverage from Tallinn to Moscow to Sofia. Sales in 2018 exceeded 71 million Euros and in 2019 should reach 125 million Euros. Established in 2014, Swixx has gathered outstanding pharmaceutical, rare disease, medical device as well as OTC / consumer healthcare talent under one roof. The company specializes in representing research-based pharmaceutical, biotech, rare disease, aesthetic, and self-care brands. For more info about Swixx, please visit: www.swixxbiopharma.com

Swixx BioPharma Contacts Regarding Name Change:

Legal: Gabriela Zelenkova, Corporate Counsel, Swixx BioPharma
Gabriela.Zelenkova@amicuspharma.eu, Tel: +420 777 059 431

Regulatory / Medical: Dr. Laur Saar, Swixx BioPharma
Laur.Saar@amicuspharma.eu, Tel: +372 509 2124

Quality Assurance: Dorde Dmitrasinovic, Swixx BioPharma
Dorde.Dmitrasinovic@amicuspharma.eu Tel: +386 30 220 942

Logistics: Meta Gros, Swixx BioPharma
Meta.Gros@amicuspharma.eu Tel: +386 1 2355 104

Billing: Petr Kratochvil, Swixx BioPharma
Petr.Kratochvil@amicuspharma.eu Tel: +420 773 794 618

Compliance and Internal Controls: Marcela Lassakova, Swixx BioPharma
Marcela.Lassakova@amicuspharma.eu Tel: + 420 602 258 746

Note on Unsubscribing from Swixx BioPharma's Announcement Mailing List

In accordance with GDPR (General Data Protection Regulation) provisions of the EU, we will be sending out in the course of June an opt in / opt out (unsubscribe) of Swixx announcements. Should you wish to unsubscribe / opt out before that, please send to Public Affairs Officer Maja Boskovic at Maja.Boskovic@amicuspharma.eu a one-line message „Please unsubscribe me“ and your email address will be promptly removed from our mailing list.